熱門資訊> 正文
Iterum Therapeutics非GAAP每股收益为-0.13美元
2025-08-05 19:16
- Iterum Therapeutics plc(ITRM) 0
- Cambria Global Asset Allocation ETF(GAA) 0
- WisdomTree Earnings 500 Fund(EPS) 0
- Iterum Therapeutics press release (NASDAQ:ITRM): Q2 Non-GAAP EPS of -$0.13.
- Cash and cash equivalents were $13.0 million as of June 30, 2025. Based on Iterum’s current operating plan, Iterum expects that its cash and cash equivalents as of June 30, 2025, together with $2.2 million of net proceeds raised under its at-the-market offering program from July 1, 2025 through August 1, 2025, will be sufficient to fund its operations into 2026. The foregoing estimate gives effect to Iterum’s currently planned commercial launch of ORLYNVAHTM in August 2025. As of August 1, 2025, Iterum had approximately 44.7 million ordinary shares outstanding.
More on Iterum Therapeutics
- Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
- Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026
- Iterum Therapeutics Non-GAAP EPS of -$0.10
- Seeking Alpha’s Quant Rating on Iterum Therapeutics
- Historical earnings data for Iterum Therapeutics
推薦文章
美股機會日報 | 8月非農大幅低於預期！納指期貨短線拉漲約0.7%；特斯拉盤前漲近2%
一周財經日曆 | 事關降息！中美5月CPI、PPI重磅出爐！新股「超購王」大行科工下周上市
高盛：降新鴻基地產目標價至96港元 評級「買入」
特朗普白宮宴請硅谷巨頭 各大公司CEO紛紛重申在美投資承諾
非農前糟糕就業數據引爆降息預期 10年期美債收益率創四個月新低
AI收入超預期！芯片巨頭博通交出滿分財報 神祕百億訂單帶來驚喜
Lululemon Athletica連續第二次下調全年業績指引 盤后股價一度暴跌超15%
9月5日外盤頭條：馬斯克回絕白宮科技CEO晚宴邀請 波音罷工持續無奈招募替代工人 露露檸檬股價盤后暴跌10%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
